What is it about?
Target therapy provide a few chance to cure hepatoma.
Featured Image
Why is it important?
This is case report for complete response of sorafenib for hepatocellular (HCC). It is possible, although low probability. Alpha-fetoprotein (AFP) decreased by its half-life in this case. It means that the case have early response to sorafenib.
Perspectives
Sorafenib is the only approved drug for systemic therapy in hepatocellular carcinoma (HCC). It should be tried if HCC of your patients was supposed to be a systemic diseases.
Professor Sheng-Nan Lu
Kaohsiung Chang Gung Memorial Hospital
Read the Original
This page is a summary of: Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib, OncoTargets and Therapy, May 2014, Dove Medical Press,
DOI: 10.2147/ott.s61740.
You can read the full text:
Contributors
The following have contributed to this page
